Literature DB >> 8878597

Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.

C Darras-Joly1, J P Bédos, C Sauve, P Moine, E Vallée, C Carbon, E Azoulay-Dupuis.   

Abstract

In vivo synergy with beta-lactam antibiotics and aminoglycosides has been studied only with penicillin-susceptible Streptococcus pneumoniae strains. We evaluated the interaction between amoxicillin (AMX) and gentamicin (GEN) on the basis of in vitro checkerboard and time-kill curves and of findings in a mouse model of acute bacteremic pneumonia due to a highly penicillin-resistant and -tolerant S. pneumoniae strain of serotype 19 (penicillin and AMX MICs of 4 micrograms/ml; gentamicin MIC of 16 micrograms/ml). Checkerboard results at 18 h of incubation showed indifference. With regard to AMX alone, in vitro time-kill curves demonstrated synergy between AMX (1 microgram/ml) and GEN (16 micrograms/ml) at 5 and 8 h of incubation and for AMX (16 micrograms/ml) in combination with GEN (16 micrograms/ml) at 3, 5, and 8 h of incubation. In leukopenic mice, pulmonary killing curves after a single drug injection demonstrated that AMX (100 mg/kg of body weight) with GEN (16 mg/kg) was more effective than AMX alone (P = 10(-4). With repeated-dose treatment, a synergy was apparent at 8 h after four injections with AMX (100 mg/kg) in combination with GEN (8 or 16 mg/kg) (P < or = 0.05). The cumulative survival rate with AMX (100 mg/kg) every 8 h, combined with GEN (4 or 8 mg/kg) every 8, 12, or 24 h, was better than with AMX alone. Combined use of AMX and GEN may be a valuable therapeutic alternative for pneumococcal pneumonia due to highly penicillin-resistant S. pneumoniae strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878597      PMCID: PMC163489     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

Review 2.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 3.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.

Authors:  P Moreillon; Z Markiewicz; S Nachman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

6.  Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis.

Authors:  B Fantin; B Pangon; G Potel; J M Vallois; F Caron; A Bure; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Interaction between beta-lactam antibiotics and gentamicin against Streptococcus pneumoniae in vitro and in vivo.

Authors:  N Frimodt-Møller; V Frølund Thomsen
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1987-10

8.  Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains.

Authors:  E Azoulay-Dupuis; P Moine; J P Bedos; V Rieux; E Vallee
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

Authors:  E Azoulay-Dupuis; J P Bedos; E Vallée; D J Hardy; R N Swanson; J J Pocidalo
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

10.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

View more
  11 in total

Review 1.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  Philippe Cottagnoud; Cynthia M Gerber; Marianne Cottagnoud; Martin G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.

Authors:  Matilde Gracia; Carmina Martínez-Marín; Lorena Huelves; Maria J Giménez; Lorenzo Aguilar; Antonio Carcas; Carmen Ponte; Francisco Soriano
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

6.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 7.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

8.  Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs.

Authors:  Chongshan Dai; Tingting Zhao; Xing Yang; Xilong Xiao; Tony Velkov; Shusheng Tang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

9.  The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents.

Authors:  Laura R Marks; Emily A Clementi; Anders P Hakansson
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

Review 10.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.